These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

846 related items for PubMed ID: 11926786

  • 21. Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension.
    Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Weissmann N, Schudt C, Tenor H, Seeger W, Grimminger F.
    Crit Care Med; 2002 Nov; 30(11):2489-92. PubMed ID: 12441759
    [Abstract] [Full Text] [Related]

  • 22. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group.
    Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM, Niedermeyer J, Fabel H, Seeger W.
    J Am Coll Cardiol; 2000 Jan; 35(1):176-82. PubMed ID: 10636277
    [Abstract] [Full Text] [Related]

  • 23. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
    Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL.
    Circulation; 2003 Oct 28; 108(17):2066-9. PubMed ID: 14568893
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension.
    Ghofrani HA, Friese G, Discher T, Olschewski H, Schermuly RT, Weissmann N, Seeger W, Grimminger F, Lohmeyer J.
    Eur Respir J; 2004 Feb 28; 23(2):321-6. PubMed ID: 14979511
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease.
    Schulze-Neick I, Hartenstein P, Li J, Stiller B, Nagdyman N, Hübler M, Butrous G, Petros A, Lange P, Redington AN.
    Circulation; 2003 Sep 09; 108 Suppl 1():II167-73. PubMed ID: 12970227
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
    Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB, PACES Study Group.
    Ann Intern Med; 2008 Oct 21; 149(8):521-30. PubMed ID: 18936500
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.
    Schermuly RT, Kreisselmeier KP, Ghofrani HA, Samidurai A, Pullamsetti S, Weissmann N, Schudt C, Ermert L, Seeger W, Grimminger F.
    Circ Res; 2004 Apr 30; 94(8):1101-8. PubMed ID: 15031263
    [Abstract] [Full Text] [Related]

  • 35. Inhaled iloprost as a long-term additional therapy to oral sildenafil in severe idiopathic pulmonary arterial hypertension.
    Onen ZP, Akkoca Yildiz O, Eriş Gülbay B, Karabiyikoğlu G.
    Tuberk Toraks; 2006 Apr 30; 54(2):177-81. PubMed ID: 16924576
    [Abstract] [Full Text] [Related]

  • 36. [Efficacy of oral sildenafil as rescue therapy in patients with severe pulmonary arterial hypertension chronically treated with prostacyclin. Long-term results].
    Jiménez López-Guarch C, Escribano Subias P, Tello de Meneses R, Delgado Jiménez JF, Sadia Pérez D, Velázquez Martín MT, Gómez Sánchez MA, Sáenz de la Calzada C.
    Rev Esp Cardiol; 2004 Oct 30; 57(10):946-51. PubMed ID: 15469792
    [Abstract] [Full Text] [Related]

  • 37. Hemodynamic effects of combination therapy with inhaled nitric oxide and iloprost in patients with pulmonary hypertension and right ventricular dysfunction after high-risk cardiac surgery.
    Antoniou T, Koletsis EN, Prokakis C, Rellia P, Thanopoulos A, Theodoraki K, Zarkalis D, Sfyrakis P.
    J Cardiothorac Vasc Anesth; 2013 Jun 30; 27(3):459-66. PubMed ID: 23063102
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension.
    Oliver JJ, Hughes VE, Dear JW, Webb DJ.
    Hypertension; 2010 Jul 30; 56(1):62-7. PubMed ID: 20479335
    [Abstract] [Full Text] [Related]

  • 40. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group.
    Olschewski H, Ghofrani HA, Schmehl T, Winkler J, Wilkens H, Höper MM, Behr J, Kleber FX, Seeger W.
    Ann Intern Med; 2000 Mar 21; 132(6):435-43. PubMed ID: 10733442
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 43.